IHE ETF Analysis: U.S. Pharmaceuticals | NYSE
Healthcare Equity | NYSE, USA | Market Cap: 1.619m USD | 12M Return: 44.9% | US4642888360 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 26.5M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The iShares U.S. Pharmaceuticals ETF (IHE) tracks an underlying index composed of U.S. pharmaceutical companies, including manufacturers of prescription drugs, over-the-counter medications, and vaccines. The fund adheres to an 80% policy, investing at least 80% of its assets in the component securities of its index, while retaining the flexibility to allocate up to 20% to futures, options, swap contracts, and cash equivalents. The fund is structured as non-diversified, meaning it may hold a more concentrated portfolio relative to diversified ETFs.
The pharmaceutical sector is generally characterized by high research and development costs, long product development cycles, and revenue streams protected by patents and regulatory exclusivity. Companies in this space are subject to oversight from the U.S. Food and Drug Administration (FDA), which governs drug approval, manufacturing standards, and labeling. Demand for pharmaceutical products tends to be relatively inelastic, as prescription and over-the-counter medications address ongoing medical needs, and vaccines serve both routine immunization schedules and outbreak response.
- GLP-1 obesity drugs drive pharmaceutical revenue growth
- Medicare drug price negotiations pressure sector margins
- Patent cliff expirations erode blockbuster drug sales
As of November 11, 2026, the stock is trading at USD 110.46 with a total of 178,273 shares traded. Over the past week, the price has changed by +3.50%, over one month by +10.25%, over three months by +6.65% and over the past year by +44.94%.
Current recommended Stop Loss: 107.00 (which is 3.1% or 1.4 ATR below the current price).
U.S. Pharmaceuticals has no consensus analysts rating.